DEADLINE ALERT – Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action against Express Scripts Holding Company (ESRX) and Lead Plaintiff Deadline July 5, 2016

NEW YORK, NY / ACCESSWIRE / June 30, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District Court, Southern District of New York on behalf of those who purchased shares of Express Scripts Holding Company (“Express Scripts” or the “Company”) (NASDAQ: ESRX) between February 24, 2015 and March 21, 2016 inclusive (the “Class Period”).

The complaint alleges that throughout the Class Period Express Scripts failed to disclose and/or misled investors regarding its relationship and contract with client Anthem, Inc.

On January 12, 2016, Anthem, Inc. openly threatened to cease its relationship with Express Scripts if Express Scripts would not agree to deliver more than $3 billion in annual savings to Anthem. Following this news, Express Scripts dropped $5.89 per share, or 6.88%, to close at $79.69 on January 13, 2016. Then, on March 21, 2016, Anthem charged Express Scripts, claiming that the Company violated its contract with Anthem by failing to negotiate drug pricing terms in good faith. The opening of this lawsuit exposed a battle between Express Scripts and Anthem going back as early as February 2015, and included accusations that Express Scripts had significant operational problems that interfered with its ability to properly serve Anthem and exposed Anthem to additional monitoring. Shareholders also learned that Anthem would be renegotiating its contract to pay billions of dollars less to Express Scripts, or find a competing pharmacy benefit manager, subsequently losing of Anthem’s business.

No Class has yet been certified in the above action. If you wish to review a copy of the Complaint or join the action, please visit the firm’s site: http://www.bgandg.com/#!esrx/bsz2p. To discuss this action, or for any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Express Scripts you have until July 5, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 441216